Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Apr 11;115(4):477-478.
doi: 10.1093/jnci/djad021.

Re: Clinicopathological features and outcomes comparing patients with invasive ductal and lobular breast cancer

Roberta Maltoni  1 , Maurizio Puccetti  2 , Francesca Poli  2 , Giovanni Martinelli  1 , Sara Bravaccini  1
Affiliations
Comment

Re: Clinicopathological features and outcomes comparing patients with invasive ductal and lobular breast cancer

Roberta Maltoni et al. J Natl Cancer Inst. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1.
Figure 1.
Hematoxylin–eosin stained sections of 2 classic primary lobular infiltrating carcinomas of 2 patients and for one of them, the related periuterine metastasis. A) Primary classic lobular infiltrating carcinoma of a disease-free patient after 14 years from the quadrantectomy (10x magnification, scale bar = 200 μm) (patient 1). B) Primary classic lobular infiltrating carcinoma of a patient relapsed 5 years after surgical treatment (10x magnification, scale bar = 200 μm) (patient 2). C) Periuterine metastasis of the relapsed patient (20x magnification, scale bar = 100 μm) (patient 2).
See this image and copyright information in PMC

Comment in

  • Response to Maltoni, Puccetti, Poli, et al.
    Oesterreich S, Lee AV, Carleton N. Oesterreich S, et al. J Natl Cancer Inst. 2023 Apr 11;115(4):479-481. doi: 10.1093/jnci/djad022. J Natl Cancer Inst. 2023. PMID: 36762844 Free PMC article. No abstract available.

Comment on

References

    1. Oesterreich S, Nasrazadani A, Zou J, et al. Clinicopathological features and outcomes comparing patients with invasive ductal and lobular breast cancer. J Natl Cancer Inst. 2022;114(11):1511-1522. doi: 10.1093/jnci/djac157. - DOI - PMC - PubMed
    1. Weiser R, Polychronopoulou E, Hatch SS, et al. Adjuvant chemotherapy in patients with invasive lobular carcinoma and use of the 21-gene recurrence score: a National Cancer Database analysis. Cancer. 2022;1128(9):1738-1747. - PubMed
    1. Trapani D, Gandini S, Corti C, et al. Benefit of adjuvant chemotherapy in patients with lobular breast cancer: a systematic review of the literature and metanalysis. Cancer Treat Rev. 2021;97:102205. - PubMed
    1. Conlon N, Ross DS, Howard J, Catalano JP, Dickler MN, Tan LK.. Is there a role for oncotype Dx testing in invasive lobular carcinoma? Breast J. 2015;21(5):514-519. - PMC - PubMed
    1. Maltoni R, Bravaccini S.. What is the best clinical pathological score to identify high-risk patients with lobular carcinoma of the breast who are likely to benefit from adjuvant chemotherapy? Breast Cancer Res Treat. 2019;177(1):231-232. - PubMed